Organisation paid for research Program year 2025 Source: CMS Open Payments

Ocala Oncology Center Pl

Neither a doctor nor a teaching hospital

Research payments

$4,189,201

138 payments

Through program year 2025, Ocala Oncology Center Pl is reported as receiving $4,189,201 in research payments, across 138 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $408,800 46
2024 Research $156,092 24
2023 Research $459,483 43
2022 Research $1,122,374 6
2021 Research $1,957,633 2
2020 Research $54,409 10
2019 Research $30,410 7

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $3,221,202 8 payments
  2. BeiGene, Ltd. $224,302 55 payments
  3. AbbVie, Inc. $217,148 14 payments
  4. Mirati Therapeutics, Inc. $207,120 17 payments
  5. AstraZeneca Pharmaceuticals LP $99,009 2 payments
  6. BeOne Medicines Ltd. $89,158 20 payments
  7. Pharmacyclics LLC, An AbbVie Company $76,050 8 payments
  8. Gilead Sciences, Inc. $32,430 10 payments
  9. MacroGenics, Inc. $8,410 1 payment
  10. Janssen Research & Development, LLC $7,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Clinical Trial to Assess the Efficacy and Safety of An Alternative Dosing Regimen of Ribociclib in Breast Cancer $3,160,014 5 payments
  2. A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma $239,615 53 payments
  3. A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 $125,662 7 payments
  4. a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton $99,009 2 payments
  5. A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma $75,429 4 payments
  6. Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma $70,581 6 payments
  7. A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy $56,076 7 payments
  8. A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car $52,345 17 payments
  9. Pcyc-1141-Ca $49,389 6 payments
  10. Two Arm Randomized Phase 3 Study in High Risk Nsclc Comparing Canakinumab VS Placebo in Adjuvant Setting $49,188 2 payments
What the money was spent on Research payments · program years 2019–2025
  1. Non-patient care $176,440 10 payments
  2. Patient care $39,090 8 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record